Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
Part of paid clinical trials in Chandler, Arizona.
- Sponsor
- HRI-MAIL-NIT
- Study ID
- NCT06986447
- Status
- Enrolling By Invitation
Conditions
- MASLD
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- MetALD
- Metabolic Dysfunction-Associated Steatotic Liver Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Study Details
This is a general clinical research protocol to study the clinical evaluation, investigation and long-term follow up of patients who have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MetALD (MASLD and increased alcohol intake), and to assess the usefulness and accuracy of non-invasive testing such as MRI and Fibroscan in tracking the progression of disease. The protocol is designed to follow the natural history, pathogenesis, interventions, treatment response, comorbidities, major liver related outcomes, and major cardiac events in patients with MASLD and MetALD, especially those with significant and advanced fibrosis. Data will be collected to help further the understanding of non-invasive testing with the hopes of lessening the need for liver biopsies in phase 3 clinical trials of MASLD and in clinical practice. Additionally, the study will aim to define the natural history of MetALD, an area that is poorly understood.
Key Dates
- Start date
- Oct 25, 2025
- Status verified
- Mar 2026
- Primary completion
- Feb 28, 2029
- Completion
- Jun 30, 2029
Study Design
- Enrollment
- 1,689 participants (estimated)
Arms
- Arm: MASLD (Cohort A)Patients with metabolic dysfunction-associated steatotic liver disease
- Arm: MetALD (Cohort B)Patients with metabolic dysfunction-associated steatotic liver disease and increased alcohol intake
Primary Outcome Measure
Occurrence of major adverse liver outcomes (MALO) [ Time Frame: 2 years ]
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Arizona Liver Health | Chandler | Arizona | 85224 | - |
| Arizona Liver Health | Peoria | Arizona | 85381 | - |
| Arizona Liver Health | Tucson | Arizona | 85712 | - |
| CRIOH | Westlake | Ohio | 44145 | - |
| Houston Research Institute - Dairy Ashford | Houston | Texas | 77079 | - |
| Houston Research Institute - Medical Center | Houston | Texas | 77030 | - |
| Houston Research Institute - Pasadena | Pasadena | Texas | 77505 | - |
| Houston Research Institute - Sugar Land | Sugar Land | Texas | 77478 | - |
Find similar trials in Chandler, AZ
Related Studies
- NAFLD Clinical Care PathwayRecruiting · VA Office of Research and Development · Houston, Texas
- A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)PHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Chandler, Arizona
- A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIVPHASE2 · Recruiting · Naga P. Chalasani · Birmingham, Alabama
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)PHASE3 · Recruiting · Eli Lilly and Company · Tuscaloosa, Alabama